Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001979217 | SCV002252699 | uncertain significance | Immunodeficiency, common variable, 7 | 2024-02-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 711 of the CR2 protein (p.Ser711Asn). This variant is present in population databases (no rsID available, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with CR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1464821). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002569222 | SCV003627072 | uncertain significance | Inborn genetic diseases | 2022-07-19 | criteria provided, single submitter | clinical testing | The c.2132G>A (p.S711N) alteration is located in exon 11 (coding exon 11) of the CR2 gene. This alteration results from a G to A substitution at nucleotide position 2132, causing the serine (S) at amino acid position 711 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV001979217 | SCV004180434 | uncertain significance | Immunodeficiency, common variable, 7 | 2023-04-11 | criteria provided, single submitter | clinical testing |